Role of CYP2E1 in Diethylnitrosamine-Induced Hepatocarcinogenesis In vivo

Cancer Research - Tập 67 Số 23 - Trang 11141-11146 - 2007
Jin Seok Kang1, Hideki Wanibuchi1, Keiichirou Morimura1, Frank J. Gonzalez2, Shoji Fukushima1
11Department of Pathology, Osaka City University Medical School, Osaka, Japan and
22Laboratory of Metabolism, National Cancer Institute, NIH, Bethesda, Maryland

Tóm tắt

Abstract CYP2E1 metabolizes many low–molecular weight toxins and carcinogens. Some in vitro experiments suggest that CYP2E1 may be involved in the metabolic activation of diethylnitrosamine. However, there has been no direct evidence demonstrating a role for CYP2E1 in diethylnitrosamine-mediated carcinogenesis in vivo. To clarify this, we carried out a diethylnitrosamine-induced hepatocarcinogenesis experiment using Cyp2e1-null mice. Male 14-day-old wild-type and Cyp2e1-null mice were treated with diethylnitrosamine (10 mg/kg of body weight) and killed at weeks 24 and 36 after diethylnitrosamine treatment for investigation of tumors and at 6, 24, and 48 h for examination of apoptosis and gene expression. Liver weights of Cyp2e1-null mice were significantly different at weeks 24 and 36 compared with wild-type mice (P < 0.01). Liver tumor incidences of Cyp2e1-null mice were significantly decreased at weeks 24 and 36 compared with wild-type mice (P < 0.01). Cyp2e1-null mice showed significant decrease in the multiplicities of hepatocellular adenoma at weeks 24 and 36 (P < 0.05 and P < 0.01, respectively), and of hepatocellular carcinoma at week 36 (P < 0.01) compared with wild-type mice. Apoptotic index and caspase-3 and/or Bax mRNA expression of Cyp2e1-null mice were significantly different at 6, 24, and 48 h after diethylnitrosamine treatment compared with wild-type mice (P < 0.05). We conclude that Cyp2e1-null mice show lower tumor incidence and multiplicity compared with wild-type mice in diethylnitrosamine-induced hepatocarcinogenesis. It is suggested that CYP2E1 completely participates in diethylnitrosamine-induced hepatocarcinogenesis, and high frequency of tumors in wild-type mice could be associated with the increased apoptosis. [Cancer Res 2007;67(23):11141–6]

Từ khóa


Tài liệu tham khảo

Guengerich FP. Cytochromes P450, drugs, and diseases. Mol Interv 2003; 3: 194–204.

Guengerich FP. Metabolism of chemical carcinogens. Carcinogenesis 2000; 21: 345–51.

Gonzalez FJ. The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis. Toxicol Lett 2001; 120: 199–208.

Yoo JS, Guengerich FP, Yang CS. Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res 1988; 48: 1499–504.

Fujita K, Kamataki T. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase. Mutat Res 2001; 483: 35–41.

Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res 2005; 569: 101–10.

Hoffmann D, Adams JD, Piade JJ, et al. Chemical studies on tobacco smoke LXVIII. Analysis of volatile and tobacco-specific nitrosamines in tobacco products. IARC Sci Publ 1980;507–16.

Sen NP, Seaman S, McPherson M. Further studies on the occurrence of volatile and non-volatile nitrosamines in foods. IARC Sci Publ 1980;457–65.

IARC. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: some N-nitroso compounds. IARC Monogr Eval Carcinog Risks Chem Man 1978; 17: 1–349.

Diwan BA, Rice JM, Ward JM, et al. Inhibition by phenobarbital and lack of effect of amobarbital on the development of liver tumors induced by N-nitrosodiethylamine in juvenile B6C3F1 mice. Cancer Lett 1984; 23: 223–34.

Jang JJ, Weghorst CM, Henneman JR, et al. Progressive atypia in spontaneous and N-nitrosodiethylamine-induced hepatocellular adenomas of C3H/HeNCr mice. Carcinogenesis 1992; 13: 1541–7.

Tamano S, Merlino GT, Ward JM. Rapid development of hepatic tumors in transforming growth factor α transgenic mice associated with increased cell proliferation in precancerous hepatocellular lesions initiated by N-nitrosodiethylamine and promoted by phenobarbital. Carcinogenesis 1994; 15: 1791–8.

Jensen MR, Factor VM, Fantozzi A, et al. Reduced hepatic tumor incidence in cyclin G1-deficient mice. Hepatology 2003; 37: 862–70.

Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 1996; 71: 57–81.

Yamazaki H, Oda Y, Funae Y, et al. Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylamine to products genotoxic in an acetyltransferase-overexpressing Salmonella typhimurium strain (NM2009). Carcinogenesis 1992; 13: 979–85.

Kushida H, Fujita K, Suzuki A, et al. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase. Carcinogenesis 2000; 21: 1227–32.

Lee SS, Buters JT, Pineau T, et al. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996; 271: 12063–7.

Yamazaki H, Inui Y, Yun CH, et al. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992; 13: 1789–94.

Camus AM, Geneste O, Honkakoski P, et al. High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol Carcinog 1993; 7: 268–75.

Goldsworthy TL, Fransson-Steen R. Quantitation of the cancer process in C57BL/6J, B6C3F1 and C3H/HeJ mice. Toxicol Pathol 2002; 30: 97–105.

Drinkwater NR, Ginsler JJ. Genetic control of hepatocarcinogenesis in C57BL/6J and C3H/HeJ inbred mice. Carcinogenesis 1986; 7: 1701–7.

Vesselinovitch SD, Koka M, Mihailovich N, et al. Carcinogenicity of diethylnitrosamine in newborn, infant, and adult mice. J Cancer Res Clin Oncol 1984; 108: 60–5.

Maeda S, Kamata H, Luo JL, et al. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121: 977–90.

Mates JM, Perez-Gomez C, Nunez de Castro I. Antioxidant enzymes and human diseases. Clin Biochem 1999; 32: 595–603.

Schattenberg JM, Wang Y, Rigoli RM, et al. CYP2E1 overexpression alters hepatocyte death from menadione and fatty acids by activation of ERK1/2 signaling. Hepatology 2004; 39: 444–55.

Lindros KO, Cai YA, Penttila KE. Role of ethanol-inducible cytochrome P-450 IIE1 in carbon tetrachloride-induced damage to centrilobular hepatocytes from ethanol-treated rats. Hepatology 1990; 12: 1092–7.

Liu H, Jones BE, Bradham C, et al. Increased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-α. Am J Physiol Gastrointest Liver Physiol 2002; 282: G257–66.

Koop DR, Chernosky A, Brass EP. Identification and induction of cytochrome P450 2E1 in rat Kupffer cells. J Pharmacol Exp Ther 1991; 258: 1072–6.

Nieto N, Friedman SL, Greenwel P, et al. CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology 1999; 30: 987–96.

Arsura M, Cavin LG. Nuclear factor-κB and liver carcinogenesis. Cancer Lett 2005; 229: 157–69.

Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 2004; 44: 27–42.

Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999; 59: 1693–700s.

Finucane DM, Bossy-Wetzel E, Waterhouse NJ, et al. Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J Biol Chem 1999; 274: 2225–33.

Jurgensmeier JM, Xie Z, Deveraux Q, et al. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 1998; 95: 4997–5002.

Greenbaum LE. Cell cycle regulation and hepatocarcinogenesis. Cancer Biol Ther 2004; 3: 1200–7.

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307–10.

Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29: 684–8.

Thông tin
Thông tin xuất bản

Cancer Research

Tập 67 Số 23

11141-11146

Thông tin tác giả